Heart Failure

Investigators writing in BMJ Open called for “a complete restoration of FOURIER trial data.” Amgen, the maker of evolocumab, said it stood by the data.

The American Journal of Managed Care® covered thousands of miles in 2022, virtually and in person, criss-crossing the country and the world to deliver the latest clinical data, trial results, and drug developments.

In heart failure this year, value-based care, left ventricular ejection fraction, and disease prevention were among the most popular topics discussed.

At this year’s American Heart Association (AHA) Scientific Sessions, held November 5-7 in Chicago, Illinois, hot topics for discussion included VICTORIA trial data and the great need for new antihypertensive agents to reduce health care disparities.

The American College of Cardiology’s 71st Scientific Session covered how to address the impact of social determinants of health on cardiovascular outcomes, understanding the latest developments in digital health, and the role of COVID-19 on heart health.

This analysis evaluates the relationship between hospital care delivery network fragmentation and in-hospital and 90-day outcomes. These networks may be novel targets for improving outcomes.

Predictive analytics–driven disease management outperforms standard of care among patients with chronic heart failure.

All-cause mortality was investigated among individuals who had heart failure as it related to their daily caloric intake and energy outcome.

Researchers pulled data from the FDA’s Adverse Event Reporting System to analyze cardiac arrhythmia–related outcomes among patients on a mono or combination regimen for cancer treatment that included immune checkpoint inhibitors (ICIs).

Study authors initiated this study because of a lack of data on arrhythmia trends among pregnant women who have been hospitalized for delivery, accounting for their age, comorbidities, and obesity status.

This international study, from investigators in Germany and Austria, looked at the effect sacubitril/valsartan can have among patients who have heart failure with reduced ejection fraction (HFrEF) and the impact on their cardiac autonomic nervous system.

Patients with heart failure frequently suffer from fluid overload, and for those with heart failure with reduced ejection fraction (HFrEF) also suffering from septic shock—a condition often treated with fluids—more data are needed on outcomes following fluid administration.

The limited data on heart failure (HF)-related mortality among young adults, those aged 15 to 44 years, prompted this analysis of data from 1999 to 2019 that considered HF as a contributing or underlying cause of death.

Despite known racial disparities in access to advanced heart failure (HF) treatments, the reasons for this continue to require further exploration. In this new study, investigators searched for associations between ventricular assist device use and heart transplant and race (Black or White).

The impact of the COVID-19 pandemic on pediatric heart transplant waiting list times was evaluated in this new study that used data from the United Network for Organ Sharing.

Outcomes following a heart attack, or myocardial infarction (MI), were assessed among a large patient population in Ontario, Canada.

This potential outcome was particularly evident among study participants who had heart failure (HF) with preserved ejection fraction, a subtype of HF with few therapeutic options.

The panel of experts provide their final insights regarding unmet needs surrounding treatment management of heart failure.

Experts share their thoughts on payer and provider perceptions surrounding affordable HF care, as well as strategies to manage care-associated costs.

Multiple comorbidities lead to an emphasis on multidisciplinary care management when determining the most effective HF treatment strategies.

Russell Rotondo, MD, FACC, medical director of clinical strategy and innovation for cardiology at Cohere Health, discusses the myriad positive ways utilization management programs can have an impact on patient outcomes in cardiovascular care.

Amresh Raina, MD, is director of the Advanced Heart Failure and Pulmonary Hypertension Program at Allegheny General Hospital and the Allegheny Health Network in Pittsburgh, Pennsylvania.

This study investigated long-term mortality outcomes following transcatheter aortic valve replacement (TAVR) among patients with a left ventricular ejection fraction (LVEF) below 50% and comorbid severe aortic stenosis.

This new study investigated risk factors for cardiovascular disease, including heart failure, among hospitalized patients with a recent history of methamphetamine use and priority patient populations to target.

People who experienced childhood poverty and other adversities are at greater risk of premature death in adulthood; Pfizer’s COVID-19 vaccine is 73% effective in protecting children younger than 5 years; women experience more symptoms of heart failure and other cardiovascular diseases than men.

This subanalysis of data from the ELDERCARE-AF trial investigated the safety and effectiveness of a 15-mg daily dose of the factor Xa inhibitor among older patients who have atrial fibrillation (AFib).

Entresto (sacubitril/valsartan) is approved for use in adult and pediatric heart failure, and previous research shows it to be cost-effective in the long term.

The REVEAL-HF study investigated using risk scores to improve patient outcomes through targeted interventions, including treatment initiation and intensity, end-of-life care, and hospitalization and mortality risks.

New heart failure guidelines redefine stages of the disease to emphasize prevention, said Biykem Bozkurt, MD, PhD, but more must be done by payers to identify those at high risk.

Martha Gulati, MD, MS, kicked off the symposium “Saving the Hearts of Women Through Prevention” ahead of the 2022 Congress of the American Society for Preventive Cardiology, which took place Friday through Sunday in Louisville, Kentucky.